Skip to main content
v2026.11,986 entries · CC-BY 4.0

21 CFR 211.84: Testing and Release of Components, Containers and Closures

What 21 CFR 211.84 requires: hold, sample, identity-test and release or reject incoming components, containers and closures, and the limits on supplier COAs.

Written and maintained by CASRAI Editorial Board

Published

On this page

21 CFR 211.84 is the section of the U.S. current good manufacturing practice (CGMP) rules for finished pharmaceuticals that governs testing and the approval or rejection of components, drug product containers and closures. It requires that every lot be held back from use until it has been sampled, tested or examined as appropriate and released by the quality control unit; that representative samples be taken from each shipment of each lot; that at least one identity test be run on every component; and that only lots meeting written specifications be released, with all others rejected.

This guide reads the five paragraphs of the section in the order a quality control (QC) laboratory meets them, ties the supplier-report allowance to FDA’s own questions and answers, and uses FDA’s diethylene glycol guidance as a worked case of why the identity test cannot be skipped. It describes the regulation as published; it is not legal advice, and your quality unit’s written procedures decide how each step is carried out at your site.

What 21 CFR 211.84 requires and who runs it

Section 211.84 sits in Subpart E (control of components and drug product containers and closures) of 21 CFR Part 211, which applies to finished pharmaceuticals. For the map of the whole Part, see the 21 CFR 210 and 211 subpart map; for the wider regime, see current good manufacturing practice. The official heading is “Testing and approval or rejection of components, drug product containers, and closures”. The text read on the eCFR and on Cornell Law’s Legal Information Institute on 2026-11-17 carries the source note 43 FR 45077 (September 29, 1978), as amended at 63 FR 14356 (March 25, 1998) and 73 FR 51932 (September 8, 2008).

Two roles matter throughout. The manufacturer samples and tests, or validates a supplier’s testing; the quality control unit releases or rejects. Paragraph (a) names the quality control unit as the body that releases a lot for use, so a lab result alone never releases material.

Paragraph (a): hold every lot until it is released

Each lot of components, drug product containers and closures must be withheld from use until the lot has been sampled, tested or examined, as appropriate, and released for use by the quality control unit. The practical consequence is a status system: material that has arrived but not been released is not available to production. Section 211.82, which precedes it, requires visual examination on receipt for labeling, container damage or broken seals, and contamination, and storage under quarantine until the material has been tested or examined and released (read at Cornell LII, 2026-11-17).

Paragraph (b): representative samples of each shipment of each lot

Representative samples of each shipment of each lot must be collected for testing or examination. The number of containers sampled and the amount taken from each container are to be based on criteria the regulation lists: statistical criteria for component variability, confidence levels and degree of precision desired, the past quality history of the supplier, and the quantity needed for analysis and for reserve samples where 211.170 requires them.

FDA’s question-and-answer document on control of components says the CGMP regulations leave the number of containers to sample to each manufacturer, as long as the sampling plan is scientifically sound, leads to representative samples and follows the principles of 211.84(b). It adds a caveat: samples are to be taken by the drug product manufacturer from containers after receipt, and pre-shipment samples or so-called piggyback samples are generally not acceptable (FDA QandA page, content current as of 2022-11-16, read 2026-11-17).

Paragraph (c): how samples are collected

Paragraph (c) is a short procedure with six numbered requirements, and each one is an auditable behaviour in the sampling area:

  1. Containers selected are cleaned when necessary so that contaminants are not introduced into the component.
  2. Containers are opened, sampled and resealed in a way designed to prevent contamination of their contents and of other components, containers or closures.
  3. Sterile equipment and aseptic sampling techniques are used when necessary.
  4. If a component must be sampled from the top, middle and bottom of its container, those subdivisions are not composited for testing.
  5. Sample containers are identified so that the material name, lot number, container sampled, date of sampling and the name of the person who collected the sample can be determined.
  6. Containers from which samples have been taken are marked to show that samples were removed.

FDA’s questions and answers address compositing directly: the regulation prohibits it only for subdivisions drawn from a single container, in 211.84(c)(4). Whether samples from different containers may be pooled for an identity test is a separate question the document answers on its own terms, so read that answer before writing a pooling rule into a procedure.

Paragraph (d): what the samples must be tested for

Paragraph (d) has six parts. The first is the one most inspections turn on.

Identity: (d)(1)

At least one test must be conducted to verify the identity of each component of a drug product, and specific identity tests, if they exist, must be used. A “specific” test is one that distinguishes the material from the others it could be confused with; a test that several materials would pass is not specific in the sense the section intends.

Conformity with specifications: (d)(2) and (d)(3)

Each component must be tested for conformity with all appropriate written specifications for purity, strength and quality. Containers and closures must be tested for conformity with their written specifications. Both paragraphs contain the supplier-report allowance covered in the next section.

Microscopic, extraneous-matter and microbiological examination: (d)(4) to (d)(6)

  • (d)(4): components are microscopically examined when appropriate.
  • (d)(5): each lot of a component, container or closure liable to contamination with filth, insect infestation or other extraneous adulterant is examined against established specifications for that contamination.
  • (d)(6): each lot with potential for microbiological contamination that is objectionable in view of its intended use is subjected to microbiological tests before use.

Paragraph (e): release or reject

Any lot that meets the written specifications of identity, strength, quality and purity, and the related tests under paragraph (d), may be approved and released for use. Any lot that does not meet them must be rejected. The word “may” for approval and “shall” for rejection is deliberate in the text: meeting specifications permits release by the quality control unit, while failing them leaves no discretion.

When a supplier’s report of analysis can replace testing

The allowance in (d)(2) is the most misread part of the section. The regulation lets a manufacturer accept a supplier’s report of analysis in lieu of its own testing against specifications, but only on two conditions that run together. The table below separates what the text lets a manufacturer rely on from what it keeps with the manufacturer.

Item Supplier’s report may replace manufacturer testing? What the manufacturer must still do
Component: purity, strength, quality tests ((d)(2)) Yes, in lieu of testing by the manufacturer Run at least one specific identity test on the component, and establish the reliability of the supplier’s analyses through appropriate validation of the supplier’s test results at appropriate intervals
Component: identity ((d)(1)) No Conduct at least one identity test; use specific identity tests where they exist
Container or closure: conformity tests ((d)(3)) Yes, a certificate of testing may be accepted Conduct at least a visual identification, and validate the reliability of the supplier’s test results at appropriate intervals

FDA’s questions and answers restate this for active pharmaceutical ingredient certificates: a manufacturer that accepts an API supplier’s certificate of analysis rather than testing must still perform the identity test itself and must validate the supplier’s results. For what a certificate of analysis contains and what it can and cannot prove, see the certificate of analysis guide, and for the supplier side of the validation see the supplier audit guide.

Worked case: why identity is tested on every lot

FDA’s guidance on testing glycerin, propylene glycol, maltitol solution, hydrogenated starch hydrolysate, sorbitol solution and other high-risk components for diethylene glycol (DEG) and ethylene glycol (EG), Revision 1 (May 2023, read 2026-11-17), applies 211.84 directly. It cites 211.84(a), (b), (d)(1) and (e), and it points to earlier poisoning incidents in which manufacturers had relied on a supplier’s certificate of analysis whose chain of custody was unknown, sometimes a copy on a distributor’s letterhead.

The guidance’s operative point: when the identity testing in the USP-NF monograph for the material includes a limit test for DEG and EG, the manufacturer must run it on representative samples of each shipment of each lot and find no more than 0.10 percent DEG and EG before using the material. The guidance is nonbinding, but it shows how the section’s pieces combine. Paragraph (a) holds the lot, (b) requires samples of each shipment, (d)(1) makes the specific identity test the manufacturer’s own, and (e) rejects the lot if it fails.

A sequence a QC laboratory can follow

The regulation does not prescribe a procedure, so the sequence below is an editorial reading of how the sections fit together, not a quotation. Every step maps to a paragraph you can cite in a written procedure.

  1. Receive and examine visually for labeling, damage, broken seals and contamination (211.82(a)); place in quarantine (211.82(b)).
  2. Set the sampling plan for each shipment of each lot against the criteria in 211.84(b), and record the reasoning, since FDA expects the plan to be scientifically sound.
  3. Collect samples after receipt using the practices in 211.84(c), with the identification and container marking it lists.
  4. Perform the identity test and any other (d) tests the material requires; where a supplier report replaces testing, keep the validation record that supports the reliability of the supplier’s results.
  5. Compare results with written specifications and pass them to the quality control unit.
  6. The quality control unit releases a conforming lot or rejects a non-conforming one (211.84(e)).

Common mistakes

  • Treating the certificate of analysis as the identity test. The supplier-report allowance never covers (d)(1); the manufacturer’s own identity test is a condition of using it.
  • Using pre-shipment or piggyback samples. FDA says samples are to be taken by the manufacturer from containers after receipt, and pre-shipment samples are generally not acceptable.
  • Compositing top, middle and bottom subsamples of one container. 211.84(c)(4) prohibits it.
  • Accepting a supplier report with no validation record. Reliability must be established through validation at appropriate intervals; a one-time review of a certificate does not show an interval.
  • Releasing in the laboratory rather than the quality unit. Paragraph (a) assigns release to the quality control unit.
  • Incomplete sample labels. Paragraph (c)(5) lists five items, including who collected the sample and from which container.

The data table below summarises the paragraphs of 211.84. Neighbouring sections in the same subpart cover receipt and quarantine (211.82), storage (211.80, cross-referenced by 211.82(b)) and sampling reserve requirements (211.170, cross-referenced by 211.84(b)). Read the paragraph you rely on in the current eCFR text before citing it, since the regulation can be amended after the date read here.

Sources

Data: 21 CFR 211.84 paragraph-by-paragraph requirements and who acts

Paragraphs of 21 CFR 211.84 compiled into one table showing the requirement, the party the text assigns it to, and the evidence a QC laboratory would hold. Compiled from the regulation text as read on Cornell LII and the eCFR; the final column is an editorial reading, not regulatory wording.

Coverage: United States.

21 CFR 211.84 paragraph-by-paragraph requirements and who acts
ParagraphTopicRequirementWho actsTypical record (editorial)
211.84(a)HoldWithhold each lot of components, containers and closures from use until sampled, tested or examined as appropriate and releasedQuality control unit releasesRelease status of the lot
211.84(b)Sampling planCollect representative samples of each shipment of each lot; size set by variability, confidence, precision, supplier history and analysis and reserve quantityManufacturer sets a plan; criteria listed in textBasis of the plan
211.84(c)(1)-(3)Sampling hygieneClean containers when necessary; open, sample and reseal to prevent contamination; sterile equipment and aseptic technique when necessaryPerson samplingMethod used
211.84(c)(4)CompositingDo not composite top, middle and bottom subdivisions of one containerPerson samplingSeparate samples
211.84(c)(5)-(6)IdentificationIdentify sample containers by material, lot, container, date and collector; mark sampled containersPerson samplingLabels and container marks
211.84(d)(1)IdentityAt least one identity test per component; specific identity tests where they existManufacturer; not replaceable by a supplier reportIdentity test result
211.84(d)(2)-(3)SpecificationsTest components, containers and closures against written specifications; supplier report or certificate may substitute if identity or visual identification is done and supplier reliability is validated at intervalsManufacturer, with validationTest results or validation record
211.84(d)(4)-(6)Other examinationsMicroscopic examination when appropriate; filth and infestation examination; microbiological tests before use where objectionable contamination is possibleManufacturerExamination results
211.84(e)DispositionRelease lots meeting specifications; reject lots that do notQuality control unitApprove or reject decision

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about 21 CFR 211.84: Testing and Release of Components, Containers and Closures

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →